Indegene drove sales for a global pharma giant's new specialty neurology product targeting relapsing multiple sclerosis, amplifying launch efforts in underperforming whitespace segments. Challenges included maximizing Rx from non-interacting, low-prescribing HCPs (treating ≤3 patients) with minimal face-to-face interactions, plus high post-launch sales/marketing costs at 28% of revenue. Indegene's software enabled pilot-testing tele/video detailing and nonpersonal initiatives on whitespace audiences, deploying targeted strategies to boost engagement, cut costs, and drive prescriptions efficiently.

Join for free to read